TECOS is a phase III multinational trial, conducted in 38 countries across Australasia, Asia, Europe, North America, South America, India and South Africa.
rial to E
utcomes after Treatment with Si
tagliptin (TECOS) investigates whether giving people with type 2 diabetes a drug called sitagliptin alongside their usual diabetes care regime can reduce their risk of heart attacks and strokes. Co-ordinated by DTU and Duke Clinical Research Institute (DCRI
), and sponsored by Merck & Co. Inc, the trial began in 2008 . The trial involves over 14,700 people with type 2 diabetes aged 50 years or older, who have heart and circulatory disease and whose blood glucose is not being controlled well. Each participant received either sitagliptin or a placebo (dummy drug) and are followed for three to five years. More information on the trial can be found on the DTU website